Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells

T. J. Eberlein, M. Rosenstein, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Few examples exist of the effective treatment of established syngeneic solid tumors using specific adoptive immunotherapy. A major limitation to the application of adoptive immunotherapy has been the lack of techniques to provide sufficiently large numbers of lymphoid cells with appropriate specific antitumor activity. Recently, we have explored the possible use of lymphoid cells expanded in Interleukin-2 (IL-2) for the adoptive immunotherapy of syngeneic murine tumors. IL-2, free of lectin, (LF-IL-2) is capable of selectively growing activated lymphoid cells as well as augmenting the generation of cytotoxic cells in vitro. Using these techniques, we have previously reported that cells specifically sensitized and then expanded in LF-IL-2 were capable of accelerating allogeneic skin graft rejection when adoptively transferred to normal hosts. Recently, we established long-term T-lymphoid lines specifically lytic for the syngeneic FBL-3 lymphoma and used these cells with cyclophosphamide to successfully treat animals with disseminated micrometastatic tumor. In this report, we have extended our observations to the treatment of an established solid syngeneic footpad tumor at a time when this tumor is also disseminated throughout the host.

Original languageEnglish (US)
Pages (from-to)396-398
Number of pages3
JournalTransplantation Proceedings
Volume15
Issue number1
StatePublished - 1983
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
Cultured Cells
Interleukin-2
T-Lymphocytes
Lymphocytes
Neoplasms
Graft Rejection
Lectins
Cyclophosphamide
Lymphoma
Skin
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells. / Eberlein, T. J.; Rosenstein, M.; Rosenberg, S. A.

In: Transplantation Proceedings, Vol. 15, No. 1, 1983, p. 396-398.

Research output: Contribution to journalArticle

@article{cf985cf4035647718b2b5877cd6df329,
title = "Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells",
abstract = "Few examples exist of the effective treatment of established syngeneic solid tumors using specific adoptive immunotherapy. A major limitation to the application of adoptive immunotherapy has been the lack of techniques to provide sufficiently large numbers of lymphoid cells with appropriate specific antitumor activity. Recently, we have explored the possible use of lymphoid cells expanded in Interleukin-2 (IL-2) for the adoptive immunotherapy of syngeneic murine tumors. IL-2, free of lectin, (LF-IL-2) is capable of selectively growing activated lymphoid cells as well as augmenting the generation of cytotoxic cells in vitro. Using these techniques, we have previously reported that cells specifically sensitized and then expanded in LF-IL-2 were capable of accelerating allogeneic skin graft rejection when adoptively transferred to normal hosts. Recently, we established long-term T-lymphoid lines specifically lytic for the syngeneic FBL-3 lymphoma and used these cells with cyclophosphamide to successfully treat animals with disseminated micrometastatic tumor. In this report, we have extended our observations to the treatment of an established solid syngeneic footpad tumor at a time when this tumor is also disseminated throughout the host.",
author = "Eberlein, {T. J.} and M. Rosenstein and Rosenberg, {S. A.}",
year = "1983",
language = "English (US)",
volume = "15",
pages = "396--398",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells

AU - Eberlein, T. J.

AU - Rosenstein, M.

AU - Rosenberg, S. A.

PY - 1983

Y1 - 1983

N2 - Few examples exist of the effective treatment of established syngeneic solid tumors using specific adoptive immunotherapy. A major limitation to the application of adoptive immunotherapy has been the lack of techniques to provide sufficiently large numbers of lymphoid cells with appropriate specific antitumor activity. Recently, we have explored the possible use of lymphoid cells expanded in Interleukin-2 (IL-2) for the adoptive immunotherapy of syngeneic murine tumors. IL-2, free of lectin, (LF-IL-2) is capable of selectively growing activated lymphoid cells as well as augmenting the generation of cytotoxic cells in vitro. Using these techniques, we have previously reported that cells specifically sensitized and then expanded in LF-IL-2 were capable of accelerating allogeneic skin graft rejection when adoptively transferred to normal hosts. Recently, we established long-term T-lymphoid lines specifically lytic for the syngeneic FBL-3 lymphoma and used these cells with cyclophosphamide to successfully treat animals with disseminated micrometastatic tumor. In this report, we have extended our observations to the treatment of an established solid syngeneic footpad tumor at a time when this tumor is also disseminated throughout the host.

AB - Few examples exist of the effective treatment of established syngeneic solid tumors using specific adoptive immunotherapy. A major limitation to the application of adoptive immunotherapy has been the lack of techniques to provide sufficiently large numbers of lymphoid cells with appropriate specific antitumor activity. Recently, we have explored the possible use of lymphoid cells expanded in Interleukin-2 (IL-2) for the adoptive immunotherapy of syngeneic murine tumors. IL-2, free of lectin, (LF-IL-2) is capable of selectively growing activated lymphoid cells as well as augmenting the generation of cytotoxic cells in vitro. Using these techniques, we have previously reported that cells specifically sensitized and then expanded in LF-IL-2 were capable of accelerating allogeneic skin graft rejection when adoptively transferred to normal hosts. Recently, we established long-term T-lymphoid lines specifically lytic for the syngeneic FBL-3 lymphoma and used these cells with cyclophosphamide to successfully treat animals with disseminated micrometastatic tumor. In this report, we have extended our observations to the treatment of an established solid syngeneic footpad tumor at a time when this tumor is also disseminated throughout the host.

UR - http://www.scopus.com/inward/record.url?scp=0020533818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020533818&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020533818

VL - 15

SP - 396

EP - 398

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1

ER -